

## A Phase 1a/b Study of ADRX-0405 in Subjects with Select Advanced Solid Tumors

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- age 18 or older - Phase 1a: confirmed advanced solid tumors (metastatic castration resistant prostate cancer (mCRPC), gastric cancer (GC), and non-small cell lung cancer (NSCLC)) - Phase 1b: confirmed prostate adenocarcinoma that is confirmed to be castration resistant and that is intolerant/resistant to standard of care (SOC) therapies - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete inclusion criteria

---

**Exclusion Criteria:**

- active and uncontrolled central nervous system metastases - have received an anticancer or investigational therapy prior to the first dose of study drug - history of ILD/pneumonitis requiring steroid treatment within the past 2 years, current ILD/pneumonitis, or an active infection requiring systemic antibiotics (prophylactic antibiotics permitted) - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete exclusion criteria

### Conditions & Interventions

**Interventions:**

Drug: ADRX-0405

**Conditions:**

Cancer

**Keywords:**

Clinics and Surgery Center (CSC), Cancer

### More Information

**Description:** This study aims to evaluate the safety and tolerability of ADRX-0405 in people with advanced cancer and determine the optimal dose for treatment.

**Study Contact:** Emmanuel Antonarakis - [anton401@umn.edu](mailto:anton401@umn.edu)

**Principal Investigator:** Emmanuel Antonarakis

**Phase:** PHASE1

**IRB**

**Number:** STUDY00024172

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.